Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update
March 15, 2023 16:05 ET
|
Matinas BioPharma Holdings, Inc.
Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting...
Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023
March 08, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID
March 02, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its...
Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
January 30, 2023 16:01 ET
|
Matinas BioPharma Holdings, Inc.
2022 Success Has Increased Confidence to Focus LNC Delivery Platform on the Future of Medicine - Delivering Genes Prioritization on Building External Partnerships and an Internal Pipeline Centered...
Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
January 23, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids
January 12, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 02, 2022 16:02 ET
|
Matinas BioPharma Holdings, Inc.
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment...
Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022
October 27, 2022 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
October 21, 2022 07:48 ET
|
Matinas BioPharma Holdings, Inc.
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded the...
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
October 21, 2022 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...